Attention-deficit/hyperactivity disorder has long been treated mainly with stimulants, and the handful of non-stimulant alternatives on the market work through a narrow set of mechanisms. That menu just expanded. The Food and Drug Administration has approved a non-stimulant ADHD medication built on a mechanism no previously cleared drug uses, giving patients and clinicians a genuinely new option for a condition that affects millions of children and adults.
The drug the FDA approved
The newly cleared medication is centanafadine, which will be sold under the brand name Simtriyo by Otsuka Pharmaceutical. The approval, granted in late July 2026, covers the treatment of ADHD in adults and in pediatric patients aged 6 and older who weigh more than 20 kilograms, roughly 44 pounds, according to coverage of the decision. That breadth is notable, because it means a single non-stimulant can be prescribed across a wide age range rather than being limited to one group.
The clearance follows a regulatory process that Otsuka had steered through Priority Review, a designation the FDA reserves for therapies that may offer a meaningful advantage over existing treatments, after the agency accepted the application earlier in the review cycle.
Why the mechanism is different
What sets centanafadine apart is how it works in the brain. It is described as a first-in-class norepinephrine-dopamine-serotonin reuptake inhibitor, meaning it increases the availability of three neurochemicals at once. Norepinephrine and dopamine are the messengers most closely tied to attention and impulse control, and existing ADHD drugs already act on them. The addition of serotonin, which influences mood and aspects of executive function, is the feature that distinguishes this drug from everything approved before it, as clinicians reviewing the approval have emphasized.
By acting on all three systems, the medication represents a new pharmacological category rather than a variation on an old one. That matters clinically because patients who do not respond well to, or cannot tolerate, existing options may respond to a drug that engages a different combination of pathways.
How it fits among existing non-stimulants
Stimulants such as methylphenidate and amphetamine remain the most widely prescribed ADHD treatments, but they are controlled substances with abuse potential and are not suitable for every patient. The non-stimulant alternatives approved before now work through a smaller range of mechanisms, including selective norepinephrine reuptake inhibition and drugs that act on certain adrenergic receptors. Centanafadine adds a fourth mechanism to that landscape.
For families wary of stimulants, or for patients who have cycled through existing medications without success, a new non-stimulant class broadens the room to find a treatment that works. Preclinical and clinical data have suggested the drug carries a low potential for abuse, which is part of what makes a non-stimulant option attractive for long-term use.
Reported side effects
Every ADHD medication carries trade-offs, and centanafadine is no exception. In studies, the most common adverse events among children and adolescents included decreased appetite, nausea, rash, fatigue, abdominal pain and somnolence. Among adults, the most frequently reported side effects were decreased appetite and headache. Decreased appetite is a familiar concern with ADHD treatment generally, and clinicians typically monitor growth and weight in younger patients on any medication that suppresses appetite.
The overall tolerability profile reported in trials was characterized as favorable, but as with any newly approved drug, the fuller picture of how it performs will emerge as it is used more widely in everyday practice outside the controlled conditions of clinical studies.
Who could benefit
ADHD is one of the most common neurodevelopmental conditions, and its treatment is often a process of trial and adjustment, with patients and prescribers testing different drugs and doses to balance symptom control against side effects. A new mechanism increases the odds that someone who has struggled to find a workable regimen will land on one. The wide age indication also means the drug can, in principle, follow a patient from childhood into adulthood without requiring a switch to a different class simply because of age.
The approval does not displace stimulants, which remain highly effective for many people, but it strengthens the non-stimulant side of the equation for those who need or prefer to avoid controlled substances.
What comes next
With the approval in hand, the practical questions shift to availability, pricing and insurance coverage, all of which shape whether a new drug reaches the patients who could use it. Prescribing patterns for a first-in-class medication also tend to build gradually as clinicians gain familiarity with dosing and response. For now, the significance is straightforward: for the first time, ADHD can be treated with a non-stimulant that acts on norepinephrine, dopamine and serotonin together, adding a distinct option to a field that has relied on a limited set of approaches.
This article was researched and drafted with the assistance of AI and reviewed before publication.
More from Morning Overview
